Impaired cell-mediated immunity in patients with classic hemophilia.
D000328:Adult; D005169:Factor VIII / Q000009:adverse effects / Q000627:therapeutic use; D005340:Fibrinogen / Q000009:adverse effects / Q000627:therapeutic use; D005612:Freeze Drying; D006467:Hemophilia A / Q000097:blood / Q000150:complications / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007111:Immunity, Cellular; D007153:Immunologic Deficiency Syndromes / Q000209:etiology*; D007694:Killer Cells, Natural / Q000276:immunology; D007958:Leukocyte Count; D008213:Lymphocyte Activation; D008297:Male; D012397:Rosette Formation; D013601:T-Lymphocytes / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
C026912:cryoprecipitate coagulum; D005169:Factor VIII; D005340:Fibrinogen